Drug Profile
Research programme: anti-cancer therapeutics - Ryvu Therapeutics
Alternative Names: A2A/B antagonists - Ryvu Therapeutics; Adenosine pathway modulators - Ryvu Therapeutics; Dual A2A/A2B adenosine receptor antagonists - Ryvu Therapeutics; Dual A2A/A2B antagonists - Ryvu Therapeutics; RVU 330; Serine hydroxymethyltransferase 2 inhibitors - Ryvu Therapeutics; SHMT2 inhibitors - Ryvu TherapeuticsLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Selvita
- Developer Ryvu Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists; Immunomodulators; SHMT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Cancer in Poland (unspecified route)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in Poland
- 04 Oct 2019 Selvita is now called Ryvu Therapeutics